Research programme: colistin potentiators - Synereca Pharmaceuticals
Latest Information Update: 02 Oct 2014
At a glance
- Originator Synereca Pharmaceuticals
- Class Polymixins; Small molecules
- Mechanism of Action Cell membrane permeability enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acinetobacter infections
Most Recent Events
- 17 Sep 2014 Preclinical trials in Acinetobacter infections in USA (PO)